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Abstract: Lymphostatin/EHEC factor for adherence-1 is a novel large toxin represented in 
various  Gram  negative  bacteria,  highly  associated  with  the  development  of  infectious 
diarrhea  and  hemolytic  uremic  syndrome.  In  vitro  and  in  vivo  experiments  identified 
lymphostatin/EFA-1 as a toxin with a central role in the pathogenesis of Gram negative 
bacteria, responsible for bacterial adhesion, intestinal colonization, immunosuppression, 
and disruption of gut epithelial barrier function. 
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1. Introduction 
Gastrointestinal infections and diarrhea are a worldwide problem with more than 1 billion cases and 
approximately  2  million  deaths  annually [1];  80%  of  which  children  aged  6  months  to  3  years. 
Infectious diarrhea caused by Gram negative bacteria can be due to Enteropathogenic E. coli (EPEC) 
in  developing  countries [2],  and  Enterohemorrhagic  E.  coli  (EHEC)  in  developed  nations [3], 
complicated by dehydration, weight loss, and hemolytic-uremic syndrome (HUS) [4].  
Pathogenic  E.  coli  harbor  a  large  arsenal  of  pathogenicity  genes,  located  on  plasmids  and  the 
bacterial  chromosome,  and  effector  proteins.  An  example  is  the  EAF-plasmid  (EPEC  adherence 
factor) [5]  encoding  for  a  battery  of  adhesion  factors.  An  additional  example  is  the  ―locus  of 
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enterocytes effacement‖ (LEE) [6] pathogenicity island located on the bacterial chromosome, encoding 
for more than 40 proteins necessary for the type III secretion system and effector proteins that modify 
and  neutralize  host  cellular  functions.  However,  not  all  genes  encoding  for  effector  proteins  and 
associated factors implicated in Gram negative pathogenesis are located on the LEE island, and one 
such example is lifA/e-1 (lymphocyte inhibitory factor A/EHEC factor for adherence-1). Recently, it 
has become clear that lifA/efa-1 assumes a central role in the pathogenesis of infectious diarrhea. 
2. Molecular Studies 
Pathogenic E. coli, like EPEC and EHEC, cause diarrheal diseases in all age groups. EPEC strains 
predominantly colonize the small intestine and rely on the virulence plasmid-encoded bundle-forming 
pili for the formation of microcolonies (localized adherence) and LEE-encoded intimin for intimate 
attachment  to  epithelial  cells  and  effacement  of  micovilli [7].  In  contrast,  EHEC  preferentially 
colonizes the distal ileum and colon with tropism for follicle-associated epithelium [8]. Like EPEC, 
EHEC harbors the LEE pathogenicity island, but also possesses phage-encoded Shiga toxins 1 and 2 
that induce an intense inflammatory response [9].  
lifA/efa-1 is found in pathogenic, but not non-pathogenic, E. coli strains, and is detected exclusively 
in strains that are capable of attaching and effacing activity, a phenotype encoded by the LEE [10,11]. 
This  gene  is  present  in  87.5%  in  EPEC,  including  atypical  EPEC  that  do  not  bear  the  
bfp-plasmid [10,12,13], 89.7%–100% of EHEC, in particular serotypes O5, O26, O23, and O111 [11,14–17], 
rabbit  Enteropathogenic  E.  coli  (REPEC)  serotypes  89/39  and  84/110–1 [18–20],  100%  of  
Hafnia  alvei,  and  mouse  pathogen  Citrobacter  rodentium.  lifA/efa-1  is  located  on  the  bacterial 
chromosome  in  EPEC,  REPEC,  and  C.  rodentium [21].  A  similar,  large  gene  with  3,169  codons 
encoding for a putative 362 kDa product was identified on the large 93 kb to 104 kb pO157 virulence 
plasmid  in  EHEC strain O157:H7, termed  toxB/L7095 [22]. Over  its entire length, nucleotide  and 
residue similarity of toxB in comparison to lifA/efa-1 was only 28% and 47%, respectively. However, 
like lifA/efa-1 and large Clostridial cytotoxins, the N-terminus contained sequences encoding for a 
glucosyltransferase. A truncated lifA/efa-1 pseudogene (efa-1’) is located in the O island 122 at z4332 
and z4333 on bacterial chromosome of serotype O157:H7 [23].  
Interestingly, lifA/efa-1 is also present in various Chlamydia spp strains. C. muridarium harbors 
three, C. psittaci a single lifA/efa-1 gene, C. trachomaits a shortened pseudogene, whereas it is not 
represented in C. pneumonia [24]. Therefore, it is conceivable that this toxin is responsible for organ 
specificity of different Chlamyida spp strains [25].  
The association of lifA/efa-1 with the pathogenesis of infectious diarrhea was established through 
molecular studies of stool samples [26]. In contrast to typical EPEC strains, atypical EPEC lack the  
69  kb  pathogenicity  EAF-plasmid  and  express  less  bacterial  effector  proteins.  DNA  microarray 
analysis  of  182  virulence  genes  identified  lifA/efa-1  as  the  gene  with  the  strongest  statistical 
association  with  infectious  diarrhea  caused  by  atypical  EPEC  strains  among  Norwegian  children, 
recently confirmed in a patient population from Brazil presenting with acute diarrhea [27]. Toxins 2010, 2 
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Several groups have shown that lifA/efa-1 in EHEC and atypical EPEC strains can be part of larger 
novel gene cluster (O122, IRW1374, OI-122) [28], responsible for increased pathogenicity. The 29 kb 
pathogenicity complex OI-122 consists of 26 genes, is divided into three modules, and is represented 
in EHEC O157:H- with a variable repertoire in non-O157:H7 serotypes. Putative virulence genes are 
found in module 1, constituting genes Z4318, pagC, and Z4322. Module 2 is composed of Z4323, ent, 
nleB, and nleB, whereas the third module is made up by lifA/efa-1 alone [29]. Each of these modules is 
significantly  associated  with  the  development  of  HUS  in  EHEC  O157:H-,  but  only  module  3  is 
involved in non-O157 Shiga toxin-producing E. coli (STEC). Especially pagC, Z4322, ent, nleE, nleB, 
and  lifA/efa-1  appear  to  be  more  prevalent  in  HUS  caused  by  non-O157  STEC [29,30].  Further, 
preliminary phenotypic characterization identified ent, nleB, and lifA/efa-1 to be important for bacterial 
colonization, and pagC, ent, nleB, and lifA/efa-1 as factors responsible for increased virulence. Genes 
implicated  in  survival  of  infected  mice  include  ent  and  nleB,  with  nleB  possibly  modulating  the 
infectious dose of non-O157 STEC to humans, thereby contributing to the low infectious dose of this 
Gram negative pathogen. Given the association of nleB and lifA/efa-1 with the development of HUS, 
testing for the presence of both genes has been proposed for clinical identification in addition to other 
methods.  From  these  studies  it  has  become  clear  that  lymphostatin/EFA-1  does  not  act  alone. 
Interestingly, even cases of HUS caused by atypical EPEC are strictly dependent on the presence of 
lifA/efa-1 [14].  
Besides lifA/efa-1, nleB has also been characterized further regarding its biological activity. It was 
shown  that  nleB  augments  the  inhibitory  activity  of  nleE  on  Nf-kB  through  IkB  stabilization, 
preventing  its  degradation [31].  In  particular,  nleE  is  required  for  maximal  inhibition  of  TNF-α 
induced IL-8 expression in vitro, pointing to a possible immunosuppressive function of these two 
bacterial effector proteins. 
lifA/efa-1 encodes for a toxin with a calculated size of approximately 360 kDa (Figure 1), one of the 
largest known proteins in Gram negative bacteria [10]. Sequencing analysis identified three critical 
motifs also present in other pathogenic bacteria: glucosyltransferase-, protease-, and aminotransferase 
motif. The glucosyltransferase motif consists of two critical aspartic acid residues separated by a single 
codon (Figure 1; DXD), and its activity is essential in the pathogenesis of large Clostridial cytotoxins, 
inhibiting small GTPases like Ras, Rac, Rho, and Cdc42 through glycosylation [32]. The N-terminal 
putative products of lifA/efa-1 exhibits 38% amino acid similarity to Clostridium difficile toxin A and 
B [16]. The second activity associated with the pathogenesis of Gram negative bacteria is the protease 
motif, catalyzing proteolytic cleavage of the C-terminal fatty acid modification of Rho [33]. The three 
critical residues for the protease activity are a cysteine, histidine, and aspartic acid (Figure 1; C,H,D). 
No role in the pathogenicity of Gram negative bacteria has been identified for the aminotransferase 
motif, consisting of ten residues (Figure 1, TMGKALSASA). 
3. Functions of Lymphostatin/EFA-1 
Initially,  lymphostatin/EFA-1  was  characterized  as  an  immunosuppressive  bacterial  effector 
protein.  In  vitro  studies  with  T  lymphocytes  isolated  from  peripheral  blood [34],  gastrointestinal Toxins 2010, 2 
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mucosa [35], and spleen [36] have shown that lymphostatin/EFA-1 inhibits mitogen-activated cytokine 
expression. Pre-incubation of lymphocyte cultures with lysates from EPEC, EHEC, and C. rodentium 
and subsequent T cell receptor stimulation lead to a dose dependent inhibition of IL-2, IL-4, and IFN-γ 
transcription and protein expression, and proliferation [34,35,37]. This immunosuppressive effect is 
independent of secondary effects, like apoptosis, IL-10, TGF-β, or the presence of macrophages [36]. 
The  immunosuppressive  function  is  present  in  the  bacterial  supernatant  with  20-fold  increased 
inhibitory activity in comparison to bacterial cell lysates [35].  
Figure 1. lifA/efa-1 encodes for lymphostatin/EFA-1, a toxin present in EPEC, EHEC, C. 
rodentium and Chlamydiae strains. lifA/efa-1 consists of approximately 9.6 kb with a C/G 
content  of  42%  and  putative  protein  molecular  weight  of  360  kDa.  DNA  sequencing 
analysis confirmed significant similarity among various Gram negative bacteria. lifA/efa-1 
encodes for three enzymatic activities: a glycosyltransferase – (D-X-D, 1.6 kb), protease–
(C, H, D, 4.5, 4.8 kb), and aminotransferase motif (TMGKALSASA, 5.8 kb). 
 
At this time it can only be speculated about the immunosuppressive function of lymphostatin in 
Chlamydia  strains.  Chlamydiae  are  obligatory  intracellular  pathogenic  bacteria  that  are  strictly 
dependent on tryptophan. Host synthesis of tryptophan is negatively regulated by IFN-γ. IFN-γ induces 
indolamine-2,3-dioxygenase and converts L-tryptophan into L-formylkynurenin [38]. Therefore, it is 
conceivable that lymphostatin/EFA-1 from Chlamydia strains suppresses mucosal IFN-γ expression, 
allowing intracellular persistence [24].  
As mentioned above, C. trachomatis encodes for a lifA/efa-1 pseudogene with significant homology 
to C. difficile toxin A and B. Previously, it has been shown that the N-terminal glucosyltransferase 
activity in C. trachomatis induces cellular ballooning, disassembly of actin fibers, and collapse of 
cytoskeleton in epithelial cells which is morphologically identical to changes induced by Clostridial 
toxins A and B [25]. 
In addition, our group has recently shown that lymphostatin/EFA-1 regulates intestinal epithelial 
barrier  function  in  vitro  and  in  vivo [39].  Infection  of  polarized  enteric  epithelial  cells  with  
C. rodentium led to inhibition of small GTPase Cdc42 and activation of RhoA. Inhibition of Cdc42 
and activation of RhoA in Caco-2 cells were reversed in cultures incubated with C. rodentium lifA/efa-1 
glucosyltransferase and protease motif mutant strains, respectively (Figure 1, above). Inactivation of 
Cdc42  induced  disassembly  of  adherens  junctions,  whereas  stimulation  of  RhoA  disrupted  tight 
junctions in intestinal epithelial cell cultures.  Toxins 2010, 2 
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Besides  an  effect  on  the  immune  system  and  intestinal  barrier  function,  lymphostatin/EFA-1 
appears to function as an adhesion factor for EHEC and EPEC strains in vitro [16,18], hence the name. 
In  EAF-negative  EPEC,  deletion  of  chromosomal  lifA/efa-1  and  pre-incubation  with  neutralizing 
antibodies  against  lymphostatin/EFA-1  decreased  bacterial  adhesion  to  epithelial  cells.  Similar 
experiments  with  EHEC  showed  that  successive  inactivation  of  EHEC  lifA/efa-1  on  the  93  kb 
pathogenicity plasmid and chromosomal pseudogene lead to a 4- and 12-fold reduction in adhesion to 
epithelial cells in vitro, respectively [40]. However, in vivo experiments with cattle and sheep assigned 
lymphostatin/EFA-1 only a minor role in intestinal colonization. In comparison to wild type, mutation 
of lifA/efa-1 gene or pseudogene in EHEC O157:H7 had no effect on the number of adhering bacteria 
in the intestines of infected animals. Further, a genome-wide search for EHEC adhesion molecules by 
transposon mutagenesis identified 59 bacterial genes that play a role in colonization of cattle intestine, 
lifA/efa-1 was not among them [41]. This is in sharp contrast to experiments with calves [40] and 
mice [21]  as  both,  lifA/efa-1  glucosyltransferase  and  protease  motifs  were  essential  for  successful 
intestinal  colonization.  However,  colonization  studies  with  lifA/efa-1  wild  type  and  mutant  
C. rodentium in mice utilized strains with a 5’ located stop codon and weak 3’ ribosomal binding site 
and start codon in the insertion sequence. It is possible that expression of genes located downstream of 
the mutations is compromised and therefore a clear role in colonization of mouse intestine cannot be 
assigned for either motif. 
In addition to an effect on eukaryotic cellular functions, studies have shown that lymphostatin/EFA-1 
positively  regulates  endogenous  prokaryotic  protein  expression  for  genes  located  on  the  LEE 
pathogenicity island [22,42]. Mutations of lifA/efa-1 gene and pseudogene lead to an 8-fold reduction 
in bacterial espD expression, a protein critical for the type III secretion system. Similarly, inactivation 
of  toxB  decreased  production  and secretion  of adhesion molecules  EspA, EspB, and  Translocated 
intimin  receptor,  as  well  as  the  number  of  bacterial  microcolonies  on  intestinal  epithelial  cells. 
Therefore,  it  is  conceivable  that  lymphostatin/EFA-1  and  ToxB  directly  and  indirectly  regulate 
bacterial effector proteins, in particular, those involved in bacterial adhesion. However, these findings 
have not been verified in other Gram negative pathogens, like EPEC or RDEC strains.  
Like tripartite toxin A and B from Clostridium spp, lymphostatin/EFA-1 harbors an N-terminal 
glucosyltransferase motif, when expressed alone, does not glycosylate small GTPases RhoA and Rab 
in vitro with UDP-glucose as a cofactor. However, it is possible that lymphostatin/EFA-1 targets a 
single or multiple different GTPases glycosylating the preserved threonine, utilizing a UDP-hexose 
like UDP-N-acetylglucosamine or UDP-galactose. 
4. Conclusion and Future Outlook 
Lymphostatin/EFA-1  is  a  large  multi-functional  toxin  encoded  by  lifA/efa-1  and  expressed  in 
various Gram negative pathogenic bacteria. lifA/efa-1 is significantly associated with the development 
of  diarrhea  and  systemic  complications  caused  by  enteric  pathogens,  including  EPEC  and  EHEC 
strains.  Investigations  of specific  motifs implicated in the  suppression of cytokine expression and 
regulation  of  bacterial  adhesion  molecules  will  clarify  the  role  of  lymphostatin/EFA-1  in  the Toxins 2010, 2 
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pathogenesis of Gram negative bacteria. Like large Clostridial cytotoxins, it is of interest to identify 
additional intracellular pathways affected by this toxin, in particular, those involving small GTPases. 
Further, there is limited knowledge about secretion and the cellular ligand of lymphostatin/EFA-1, 
whether this toxin is cleaved into smaller subunits, and the structure of this protein which is in part 
explained by its toxicity when expressed as a recombinant protein. It remains to be determined whether 
lymphostatin/EFA-1  is  an  ideal  candidate  protein  for  vaccine  development  to  prevent  devastating 
sequelae of enteric infections. 
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